The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors

Paclitaxel is one of the most widely used antineoplastic drugs in the clinic. Unfortunately, the occurrence of cellular resistance has limited its efficacy and application. The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major memb...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Cancer Ther
Prif Awduron: Zhang, Hui, Patel, Atish, Wang, Yi-Jun, Zhang, Yun-Kai, Kathawala, Rishil J., Qiu, Long-Hui, Patel, Bhargav A., Huang, Li-Hua, Shukla, Suneet, Yang, Dong-Hua, Ambudkar, Suresh V., Fu, Li-Wu, Chen, Zhe-Sheng
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7830771/
https://ncbi.nlm.nih.gov/pubmed/28265007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0511
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg